Brief: Pharvaris Announces Positive Top-Line Phase 2 Data From The Chapter-1 Study Of Deucrictibant For The Prophylactic Treatment Of HAE Attacks

Pharvaris NV

06/12/2023 13:22

Dec 6 (Reuters) - Pharvaris NV  PHVS.O :
    * PHARVARIS ANNOUNCES POSITIVE TOP-LINE PHASE 2 DATA FROM
THE
CHAPTER-1 STUDY OF DEUCRICTIBANT FOR THE PROPHYLACTIC TREATMENT
OF HAE ATTACKS
    * PHARVARIS NV - PRIMARY ENDPOINT MET
    * PHARVARIS NV - 92.3% REDUCTION IN OCCURRENCE OF MODERATE
AND
SEVERE ATTACKS
    * PHARVARIS NV - DEUCRICTIBANT WELL-TOLERATED
    * PHARVARIS NV: 92.6% FEWER ATTACKS TREATED WITH ON-DEMAND
MEDICATION BY PARTICIPANTS
    * PHARVARIS NV: PREPARING TO SUBMIT STUDY RESULTS TO FDA BY
END OF
YEAR
    * PHARVARIS NV - IN ANALYSIS OF SECONDARY ENDPOINTS,
DEUCRICTIBANT
DEMONSTRATED CLINICALLY MEANINGFUL IMPROVEMENT IN SEVERITY OF
ATTACKS
    * PHARVARIS NV -  IN ANALYSIS OF SECONDARY ENDPOINTS,
DEUCRICTIBANT DEMONSTRATED A DECREASE IN NUMBER OF ATTACKS
TREATED WITH ON-DEMAND MEDICATION
    * PHARVARIS NV - PARTICIPANTS ON DEUCRICTIBANT TREATMENT
EXPERIENCED A MEANINGFUL IMPROVEMENT IN THEIR QUALITY OF LIFE
    * PHARVARIS NV: NO SERIOUS ADVERSE EVENTS, NO SEVERE
TREATMENT-EMERGENT ADVERSE EVENTS, AND NO ADVERSE EVENTS LEADING
TO TREATMENT DISCONTINUATION

Source text for Eikon:  ID:nGNXc0Fqcx 
Further company coverage:  PHVS.O 

 ((Reuters.Briefs@thomsonreuters.com;))